News | 09 November 2025
SMS Pharmaceuticals post Q2 FY26 consolidated PAT at Rs. 25.31 Cr
SMS Pharmaceuticals has reported total income of Rs. 243.86 crore during the period ended September 30, 2025
SMS Pharmaceuticals has reported total income of Rs. 243.86 crore during the period ended September 30, 2025
Sun Pharmaceutical Industries has reported total income of Rs. 14,948.23 crore during the period ended September 30, 2025
Sales from Novo’s GLP-1 portfolio—including Wegovy for obesity and Ozempic for type 2 diabetes reached $5.6 billion
This latest commitment brings the British pharmaceutical company’s total investment at the site to $886 million
Comirnaty, Pfizer’s COVID-19 prevention vaccine, reported global sales of $1.15 billion
The discussions come as part of the administration’s broader efforts to drive down drug prices and increase patient access to essential therapies
Adjusted EBITDA increased by 12.3 per cent to $531 million, up from $516 million in the same period last year
Senores Pharmaceuticals (SPI) acquired 51% stake in Zoraya Pharmaceuticals
During the quarter, Zydus Wellness completed the acquisition of Comfort Click Limited and its subsidiaries
Collaboration aims to deliver rapid, lab-quality testing to communities worldwide – making precision health more accessible
Cupid has been allocated approximately 23.4 million units of female condoms per year
Exemestane is a key therapeutic used in the treatment of certain types of breast cancer in postmenopausal women
Bayer remains a key partner in Ginkgo Bioworks’ growing agricultural biologicals platform
The study demonstrated strong clinical outcomes, with 94.8 per cent of subjects remaining free from major target limb amputation at one year
Teva reported third quarter revenues of $4.5 billion, an increase of 3 per cent year-over-year.
Speakers are: Dr. Alok Khullar, Senior Technology Leader, Pidilite Industries; Dr. Kamlesh Pai Fondekar, Head - R&D, Godrej Agrovet; Dr. Hiten Mehta, Head - R&D (Chlor-Alkali), Aditya Birla Chemicals; Dr. Anil Kumar Soni, Head - Application Development, R&D, Clariant Chemicals India; Dr. Rupak Paul, Deputy General Manager – Formulation, Rallis India; Dr. Manish M. Khandagale, Senior Field Application Specialist, Revvity Signals; and Pravin Prashant, Executive Editor, Indian Pharma Post
Glenmark will begin distribution in November 2025
Kulzer has consolidated the production of its core product, artificial teeth, at its facility in Germany
Subscribe To Our Newsletter & Stay Updated
